Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

52.00 -1.45 (-2.71%)
Streaming Delayed Price Updated: 12:22 PM EDT, Sep 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 529,112
Open 52.50
Bid (Size) 51.98 (100)
Ask (Size) 52.05 (200)
Prev. Close 53.45
Today's Range 51.72 - 52.62
52wk Range 44.12 - 78.48
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why CRISPR Therapeutics Stock Rocked the Market Last Month ↗
The company had fallen out of investor favor; its recovery was impressive. 
Via The Motley Fool
News headline image
Where Will CRISPR Therapeutics Stock Be in 5 Years? ↗
CRISPR's expanding pipeline could unlock significantly more value by 2031. 
Via The Motley Fool

Performance

YTD
-3.3%
-3.3%
1 Month
-2.8%
-2.8%
3 Month
+5.2%
+5.2%
6 Month
+4.1%
+4.1%
1 Year
-3.1%
-3.1%

More News

Read More
News headline image
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026 ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money? ↗
Via The Motley Fool
Topics ETFs Stocks
News headline image
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead ↗
Via The Motley Fool
News headline image
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? ↗
Via The Motley Fool
News headline image
3 Stocks With the Most Upside by the End of 2026 ↗
Via The Motley Fool
Topics Workforce
News headline image
3 Mid-Cap Growth Stocks With Monstrous Long-Term Upside ↗
Via The Motley Fool
News headline image
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating ↗
Via The Motley Fool
Topics ETFs
News headline image
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? ↗
Via The Motley Fool
News headline image
3 Reasons to Buy CRISPR Therapeutics Stock ↗
Via The Motley Fool
News headline image
Vertex’s Crinetics Deal Balances Growth with Integration Risk ↗
Via MarketBeat
News headline image
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics ↗
Via The Motley Fool
News headline image
Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
The Best Stocks to Invest $1,000 in Right Now ↗
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year ↗
Via The Motley Fool
News headline image
The Best Biotech Stocks to Buy in 2026 ↗
Via The Motley Fool
Topics ETFs
News headline image
Here's How I'd Invest $10,000 Right Now ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential ↗
Via The Motley Fool
News headline image
Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking ↗
Via The Motley Fool

Frequently Asked Questions

Is CRISPR Therapeutics AG - Common Shares publicly traded?
Yes, CRISPR Therapeutics AG - Common Shares is publicly traded.
What exchange does CRISPR Therapeutics AG - Common Shares trade on?
CRISPR Therapeutics AG - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for CRISPR Therapeutics AG - Common Shares?
The ticker symbol for CRISPR Therapeutics AG - Common Shares is CRSP on the Nasdaq Stock Market
What is the current price of CRISPR Therapeutics AG - Common Shares?
The current price of CRISPR Therapeutics AG - Common Shares is 52.00
When was CRISPR Therapeutics AG - Common Shares last traded?
The last trade of CRISPR Therapeutics AG - Common Shares was at 09/10/26 12:22 PM ET
What is the market capitalization of CRISPR Therapeutics AG - Common Shares?
The market capitalization of CRISPR Therapeutics AG - Common Shares is 4.10B
How many shares of CRISPR Therapeutics AG - Common Shares are outstanding?
CRISPR Therapeutics AG - Common Shares has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.